Park Shin-Young, Lam Wing, Cheng Yung-chi
Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06520, USA.
Cancer Res. 2002 Jan 15;62(2):459-65.
X-ray repair cross-complementing gene I protein (XRCC1) in complex with DNA polymerase beta, DNA ligase III, and poly(ADP-ribose) polymerase is important in the base excision repair process. Previously, we isolated camptothecin (CPT)-resistant cell lines (KB100 and KB300) from the human epidermoid carcinoma cell line KB by exposure to CPT. From these CPT-resistant cell lines, their revertants (KB100(rev) and KB300(rev)), which lost most of their CPT-resistant phenotype during passage in the absence of CPT, were established. In this study, we found the expression levels of XRCC1 protein in KB100 and KB300 were > or =5-fold more than in their respective revertant cell lines, whereas there was no difference in the expression of XRCC1-associated proteins such as DNA polymerase beta, DNA ligase III, poly(ADP-ribose) polymerase, and apurinic/apyrimidinic endonuclease. The degree of CPT resistance was relatively correlated with the XRCC1 protein amount. We also found XRCC1 gene amplification in CPT-resistant KB100 and KB300 cell lines. To confirm a correlation between overexpression of XRCC1 and CPT resistance, we transfected the XRCC1 gene into KB100(rev) and obtained two different transfected cell lines (clones 14 and 16). The expression levels of XRCC1 in the transfected cell lines were higher than in KB100(rev) but lower than in KB100 with no difference in XRCC1-associated protein expression levels. Resistance to CPT in transfected cell lines was 2-2.5-fold higher than in KB100(rev) in regard to growth inhibition and 4-fold higher with respect to clonogenicity. Transfected cell lines also showed increased resistance to other topoisomerase I poisons. However, the cytotoxicity of VP-16 and cisplatin was similar in both the transfected cells and KB100(rev). Similar to our CPT-resistant cell lines, the resistance of transfected cell lines was reversed by treatment with 3-aminobenzamide. These results indicate that CPT resistance in our cells could be partly attributable to the overexpression of XRCC1.
与DNA聚合酶β、DNA连接酶III和聚(ADP - 核糖)聚合酶形成复合物的X射线修复交叉互补基因I蛋白(XRCC1)在碱基切除修复过程中很重要。此前,我们通过暴露于喜树碱(CPT)从人表皮样癌细胞系KB中分离出了CPT抗性细胞系(KB100和KB300)。从这些CPT抗性细胞系中,建立了它们的回复株(KB100(rev)和KB300(rev)),这些回复株在无CPT传代过程中失去了大部分CPT抗性表型。在本研究中,我们发现KB100和KB300中XRCC1蛋白的表达水平比其各自的回复株细胞系高≥5倍,而XRCC1相关蛋白如DNA聚合酶β、DNA连接酶III、聚(ADP - 核糖)聚合酶和脱嘌呤/脱嘧啶内切酶的表达没有差异。CPT抗性程度与XRCC1蛋白量相对相关。我们还在CPT抗性的KB100和KB300细胞系中发现了XRCC1基因扩增。为了证实XRCC1过表达与CPT抗性之间的相关性,我们将XRCC1基因转染到KB100(rev)中,获得了两个不同的转染细胞系(克隆14和16)。转染细胞系中XRCC1的表达水平高于KB100(rev)但低于KB100,XRCC1相关蛋白表达水平没有差异。在生长抑制方面,转染细胞系对CPT的抗性比KB100(rev)高2 - 2.5倍,在克隆形成能力方面高4倍。转染细胞系对其他拓扑异构酶I毒物的抗性也增加。然而,转染细胞和KB100(rev)中VP - 16和顺铂的细胞毒性相似。与我们的CPT抗性细胞系类似,转染细胞系的抗性通过用3 - 氨基苯甲酰胺处理而逆转。这些结果表明我们细胞中的CPT抗性可能部分归因于XRCC1的过表达。